# Opus Point Partners Management, LLC

> Institutional holdings reported to the SEC as of Q3 2019 on Form 13F. CIK 1600175. Source: https://holderbook.com/funds/1600175-opus-point-partners-management-llc/

- Reported value: $55.3M
- Positions: 54
- Weight of the ten largest: 64.3%
- Filed: 2019-11-14

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| ISHARES TR | [IBB](https://holderbook.com/stocks/IBB/) | $20.9M | 125,000 | 37.8% | 4 |
| DIREXION SHS ETF TR | [LABUXXXX](https://holderbook.com/stocks/LABUXXXX/) | $3.1M | 99,855 | 5.6% | 4 |
| METTLER TOLEDO INTERNATIONAL | [MTD](https://holderbook.com/stocks/MTD/) | $2.3M | 3,235 | 4.1% | 4 |
| BRISTOL-MYERS SQUIBB CO | [BMY](https://holderbook.com/stocks/BMY/) | $1.7M | 33,000 | 3.0% | 3 |
| SEATTLE GENETICS INC | [SGENXXXX](https://holderbook.com/stocks/SGENXXXX/) | $1.5M | 18,020 | 2.8% | 4 |
| ILLUMINA INC | [ILMN](https://holderbook.com/stocks/ILMN/) | $1.4M | 4,721 | 2.6% | 4 |
| VERTEX PHARMACEUTICALS INC | [VRTX](https://holderbook.com/stocks/VRTX/) | $1.4M | 8,279 | 2.5% | 4 |
| IONIS PHARMACEUTICALS INC | [IONS](https://holderbook.com/stocks/IONS/) | $1.2M | 20,124 | 2.2% | 4 |
| ALNYLAM PHARMACEUTICALS INC | [ALNY](https://holderbook.com/stocks/ALNY/) | $1.1M | 13,684 | 2.0% | 4 |
| ALEXION PHARMACEUTICALS INC | [ALXN](https://holderbook.com/stocks/ALXN/) | $973.0K | 9,933 | 1.8% | 4 |
| QIAGEN NV | [QGEN](https://holderbook.com/stocks/QGEN/) | $951.0K | 28,858 | 1.7% | 4 |
| SPARK THERAPEUTICS INC | [ONCE](https://holderbook.com/stocks/ONCE/) | $941.0K | 9,699 | 1.7% | 3 |
| FORTRESS BIOTECH INC | [FBIO](https://holderbook.com/stocks/FBIO/) | $865.0K | 613,551 | 1.6% | 4 |
| PROQR THRAPEUTICS N V | [PRQR](https://holderbook.com/stocks/PRQR/) | $798.0K | 138,461 | 1.4% | 4 |
| INCYTE CORP | [INCY](https://holderbook.com/stocks/INCY/) | $791.0K | 10,659 | 1.4% | 4 |
| EXACT SCIENCES CORP | [EXAS](https://holderbook.com/stocks/EXAS/) | $771.0K | 8,534 | 1.4% | 3 |
| REGENERON PHARMACEUTICALS | [REGN](https://holderbook.com/stocks/REGN/) | $677.0K | 2,439 | 1.2% | 4 |
| BIOMARIN PHARMACEUTICAL INC | [BMRN](https://holderbook.com/stocks/BMRN/) | $654.0K | 9,700 | 1.2% | 4 |
| DECIPHERA PHARMACEUTICALS IN | [DCPH](https://holderbook.com/stocks/DCPH/) | $632.0K | 18,631 | 1.1% | 3 |
| ASCENDIS PHARMA A/S | [ASND](https://holderbook.com/stocks/ASND/) | $596.0K | 6,190 | 1.1% | 3 |
| UNIQURE NV | [QURE](https://holderbook.com/stocks/QURE/) | $560.0K | 14,215 | 1.0% | 3 |
| CELGENE CORP | [CELG](https://holderbook.com/stocks/CELG/) | $559.0K | 5,625 | 1.0% | 4 |
| CRISPR THERAPEUTICS AG | [CRSP](https://holderbook.com/stocks/CRSP/) | $542.0K | 13,214 | 1.0% | 3 |
| EPIZYME INC | [EPZM](https://holderbook.com/stocks/EPZM/) | $520.0K | 50,378 | 0.9% | 3 |
| AMARIN CORP PLC | [AMRNXXXX](https://holderbook.com/stocks/AMRNXXXX/) | $510.0K | 33,641 | 0.9% | 3 |
| BLUEPRINT MEDICINES CORP | [BPMC](https://holderbook.com/stocks/BPMC/) | $498.0K | 6,780 | 0.9% | 3 |
| AUDENTES THERAPEUTICS INC | [BOLD](https://holderbook.com/stocks/BOLD/) | $487.0K | 17,339 | 0.9% | 3 |
| G1 THERAPEUTICS INC | [GTHX](https://holderbook.com/stocks/GTHX/) | $475.0K | 20,844 | 0.9% | 3 |
| GLOBAL BLOOD THERAPEUTICS IN | [GBT](https://holderbook.com/stocks/GBT/) | $460.0K | 9,479 | 0.8% | 3 |
| BIOHAVEN PHARMACTL HLDG CO L | [BHVNXXXX](https://holderbook.com/stocks/BHVNXXXX/) | $453.0K | 10,852 | 0.8% | 3 |
| ARENA PHARMACEUTICALS INC | [ARNA](https://holderbook.com/stocks/ARNA/) | $447.0K | 9,770 | 0.8% | 3 |
| ACADIA PHARMACEUTICALS INC | [ACAD](https://holderbook.com/stocks/ACAD/) | $432.0K | 12,005 | 0.8% | 4 |
| GW PHARMACEUTICALS PLC | [GWPH](https://holderbook.com/stocks/GWPH/) | $423.0K | 3,674 | 0.8% | 3 |
| ZOGENIX INC | [ZGNX](https://holderbook.com/stocks/ZGNX/) | $389.0K | 9,725 | 0.7% | 3 |
| MACROGENICS INC | [MGNX](https://holderbook.com/stocks/MGNX/) | $384.0K | 30,075 | 0.7% | 3 |
| INTELLIA THERAPEUTICS INC | [NTLA](https://holderbook.com/stocks/NTLA/) | $380.0K | 28,490 | 0.7% | 3 |
| BIO-TECHNE CORP | [TECH](https://holderbook.com/stocks/TECH/) | $303.0K | 1,551 | 0.5% | 4 |
| IQVIA HLDGS INC | [IQV](https://holderbook.com/stocks/IQV/) | $297.0K | 1,985 | 0.5% | 4 |
| AMGEN INC | [AMGN](https://holderbook.com/stocks/AMGN/) | $294.0K | 1,518 | 0.5% | 4 |
| NEUROCRINE BIOSCIENCES INC | [NBIX](https://holderbook.com/stocks/NBIX/) | $282.0K | 3,127 | 0.5% | 4 |
| CHECKPOINT THERAPEUTICS INC | [CKPT](https://holderbook.com/stocks/CKPT/) | $281.0K | 112,760 | 0.5% | 4 |
| CHARLES RIV LABS INTL INC | [CRL](https://holderbook.com/stocks/CRL/) | $280.0K | 2,112 | 0.5% | 4 |
| UNITED THERAPEUTICS CORP DEL | [UTHR](https://holderbook.com/stocks/UTHR/) | $279.0K | 3,498 | 0.5% | 1 |
| GRIFOLS S A | [GRFS](https://holderbook.com/stocks/GRFS/) | $264.0K | 13,196 | 0.5% | 4 |
| BIOGEN INC | [BIIB](https://holderbook.com/stocks/BIIB/) | $261.0K | 1,123 | 0.5% | 2 |
| INTERCEPT PHARMACEUTICALS IN | [ICPT](https://holderbook.com/stocks/ICPT/) | $261.0K | 3,926 | 0.5% | 4 |
| GILEAD SCIENCES INC | [GILD](https://holderbook.com/stocks/GILD/) | $259.0K | 4,082 | 0.5% | 4 |
| LIGAND PHARMACEUTICALS INC | [LGND](https://holderbook.com/stocks/LGND/) | $242.0K | 2,428 | 0.4% | 3 |
| NEKTAR THERAPEUTICS | [NKTR](https://holderbook.com/stocks/NKTR/) | $235.0K | 12,927 | 0.4% | 4 |
| EXELIXIS INC | [EXEL](https://holderbook.com/stocks/EXEL/) | $232.0K | 13,132 | 0.4% | 4 |
| ALKERMES PLC | [ALKS](https://holderbook.com/stocks/ALKS/) | $227.0K | 11,632 | 0.4% | 1 |
| ULTRAGENYX PHARMACEUTICAL IN | [RARE](https://holderbook.com/stocks/RARE/) | $217.0K | 5,064 | 0.4% | 4 |
| FIBROGEN INC | [FGEN](https://holderbook.com/stocks/FGEN/) | $212.0K | 5,742 | 0.4% | 4 |
| RECRO PHARMA INC | [SCTL](https://holderbook.com/stocks/SCTL/) | $126.0K | 11,353 | 0.2% | 4 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q3 2019 | -15.4% | +1.3% | -16.6% | 86% |
| Q2 2019 | -4.7% | +3.7% | -8.4% | 87% |
| Q1 2019 | +22.2% | +13.0% | +9.2% | 80% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q3 2019 | $55.3M | 54 |
| Q2 2019 | $67.6M | 62 |
| Q1 2019 | $73.8M | 74 |
| Q4 2018 | $45.4M | 39 |